Riskpilot← Back to searchSign inGet full accessNobel Biocare AB
ABActiveOrg 5560020231Västra Hamngatan 12Manufacture of medical and dental instruments and supplies · NACE 3250Est. 1898370 employees
Revenue 2024
SEK 531,8M
-16% vs 2023
EBITDA margin
100.0%
+2055% vs 2023
Equity ratio
67.1%
Financial strength
Net profit 2024
SEK 18,7M
-15% vs 2023
| Revenue | SEK 531,8M | -16% |
| EBITDA | SEK 531,8M | +2055% |
| Net profit | SEK 18,7M | -15% |
| Total assets | SEK 1,8B | +5% |
| Equity | SEK 1,2B | +2% |
| Employees | 370 | — |
Legal name
Nobel Biocare AB
Org number
5560020231
Legal form
Aktiebolag
NACE code
3250 · Manufacture of medical and dental instruments and supplies
Founded
14 februari 1898
Share capital
SEK 317 186 000
Employees
370 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas av Sundaeus, Harrieth Eva Elisabeth i förening med en av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall - direkt eller genom hel- eller delägda företag - ha till föremål för sin verksamhet att bedriva utveckling, tillverkning och försäljning av läkemedel och andra produkter för hälso- och sjukvård samt kemisk-tekniska artiklar, medicinsk-teknisk verksamhet och att idka annan därmed förenlig verksamhet samt äga och förvalta fast och lös egendom.
Address
Västra Hamngatan 12
Phone
+4631818800
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | — | 492 140 | 563 609 | 635 184 | 531 845 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 0 | 15 999 | 54 955 | 24 675 | 531 845 |
| Depreciation & amort. | — | — | — | — | — |
| EBIT | 0 | 15 999 | 54 955 | 24 675 | 20 868 |
| Net financials | — | −3 504 | −20 823 | 2 987 | 3 056 |
| Profit before tax | 0 | 12 495 | 34 131 | 27 662 | 23 924 |
| Tax | — | −1 961 | −7 643 | −5 556 | −5 198 |
| Net profit | — | 10 534 | 26 488 | 22 106 | 18 726 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | — | 2 327 270 | 1 419 577 | 1 684 951 | 1 768 595 |
| Equity | — | 1 120 125 | 1 146 614 | 1 168 720 | 1 187 446 |
| Long-term debt | — | 0 | 0 | 0 | — |
| Short-term debt | — | 1 146 770 | 212 667 | 452 704 | 515 578 |
| Total debt | — | 1 146 770 | 212 667 | 452 704 | 515 578 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20202024
Equity ratio
67.1%
This company
38.2%
Market median
+76% vs market
20202024
Return on equity
1.6%
This company
18.4%
Market median
-91% vs market
20202024
Net profit margin
3.5%
This company
8.1%
Market median
-57% vs market
20202024
Asset turnover
0.30×
This company
1.12×
Market median
-73% vs market
20202024
Debt / equity
0.49×
This company
0.62×
Market median
+21% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
HE Chief Executive Officer | Chief Executive Officer | 2020 |
DF Chief Auditor | Chief Auditor | 2025 |
| Former (2) | ||
MG Chief Auditor | Chief Auditor | 2020 – 2024 |
MT Chief Auditor | Chief Auditor | 2024 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2025 | |
| Board of Directors | 2020 | |
| Chairman | 2020 | |
| Former (5) | ||
| Deputy Board Member | 2020 – 2022 | |
| Board of Directors | 2020 – 2025 | |
| Deputy Board Member | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2023 | |
| Deputy Board Member | 2020 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOBEL BIOCARE SERVICES AG
Nobel Biocare AB (this company)NOBEL BIOCARE DEUTSCHLAND GMBHNobel Biocare Ibérica S.A.Nobel Biocare Japan K.kNobel Biocare France S.A.S.NOBEL BIOCARE NETHERLAND B.V.Nobel Biocare Deutschland GmbhNobel Biocare Österreich GmbhNOBEL BIOCARE PORTUGAL S.A.Nobel Biocare Italia S.R.L.Nobel Biocare Magyarorsz g KftNobel Biocare Norge ASNobel Biocare Netherland B.V.Nobel Biocare Portugal S.A.NOBEL BIOCARE ÖSTERREICH GMBHNobel Biocare Danmark ASALPHABIO TECNobel Biocare Polska Sp.Z.O.O.Alphabio TecNOBEL BIOCARE DANMARK ASNobel Biocare UabNOBEL BIOCARE MAGYARORSZ G KFTNOBEL BIOCARE NORGE ASNOBEL BIOCARE IBÉRICA S.A.NOBEL BIOCARE FRANCE S.A.S.NOBEL BIOCARE JAPAN K.KNOBEL BIOCARE POLSKA SP.Z.O.O.NOBEL BIOCARE ITALIA S.R.L.NOBEL BIOCARE UABBoard members of Nobel Biocare AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Harrieth Eva Elisabeth Sundaeus | Chief Executive Officer | 0 companies |
| Mattias Gustaf Erik Olofson | Chief Auditor | 0 companies |
| David Fredrik Lawenius | Chief Auditor | 0 companies |
| Mikael Thomas Gunnar Edman | Chief Auditor | 0 companies |
| Hans Fredrik Braunstein | Deputy Board Member | 0 companies |
| Stefan Fabian Lieb | Deputy Board Member | 0 companies |
| Wonna Helen Eneblom | Board of Directors | 0 companies |
| Åke Sigvard David Andersson | Board of Directors | 0 companies |
| Magnus Andreas Pettersson | Board of Directors | 0 companies |
| Lars Fredrik Strömberg | Deputy Board Member | 0 companies |
| Adrian Schell | Chairman | 0 companies |
| Chris James Stahle | Deputy Board Member | 0 companies |
| Sören Ejvind Karlsson | Deputy Board Member | 0 companies |